Overview

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-02-05

Target enrollment:

Participant gender:

Summary

This is a biomarker study designed to test the preclinically generated hypothesis of anti-tumoral activity of denosumab in patients with early breast cancer candidates a tumour excision

Phase:

Early Phase 1

Details

Lead Sponsor:

Institut Català d'Oncologia

Collaborator:

Amgen

Treatments:

Denosumab